Dario Baratti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5001404/publications.pdf

Version: 2024-02-01

151 papers	8,736 citations	30068 54 h-index	46795 89 g-index
158 all docs	158 docs citations	158 times ranked	4334 citing authors

#	Article	IF	Citations
1	Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes. European Journal of Surgical Oncology, 2022, 48, 1590-1597.	1.0	6
2	An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. World Journal of Surgery, 2022, 46, 1336-1343.	1.6	1
3	miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma. Cancer Gene Therapy, 2022, 29, 1394-1404.	4.6	3
4	Preliminary results of a program for the implementation of laparoscopic colorectal surgery in an Italian comprehensive cancer center during the COVID-19 pandemic. Updates in Surgery, 2022, 74, 1271-1279.	2.0	1
5	Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). European Journal of Surgical Oncology, 2021, 47, 82-88.	1.0	16
6	Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. Annals of Surgical Oncology, 2021, 28, 3332-3342.	1.5	19
7	Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). European Journal of Surgical Oncology, 2021, 47, 89-100.	1.0	16
8	Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Surgical Oncology, 2021, 47, 1132-1139.	1.0	12
9	Impact of Previous Gynecologic Surgical Procedures on Outcomes of Non-Gynecologic Peritoneal Malignancies Mimicking Ovarian Cancer: Less Is More?. Annals of Surgical Oncology, 2021, 28, 2899-2908.	1.5	5
10	ASO Author Reflections: Preoperative Staging for Nongynecological Peritoneal Malignancies Mimicking Ovarian Cancerâ€"Making the Omelet without Breaking the Eggs. Annals of Surgical Oncology, 2021, 28, 2909-2910.	1.5	0
11	The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surgery, 2021, 156, e206363.	4.3	74
12	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of â€˜Italian Peritoneal Surface Malignancies Oncoteamâ€"S.I.C.O.â€™. Annals of Surgical Oncology, 2021, 28, 9060-9070.	1.5	24
13	Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study. BMJ Open, 2021, 11, e046819.	1.9	1
14	ASO Author Reflections: Prognostic Factors in Surgically Treated Peritoneal Metastases from Colorectal Cancer. Annals of Surgical Oncology, 2021, 28, 3343-3344.	1.5	0
15	Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Annals of Surgical Oncology, 2020, 27, 98-106.	1.5	26
16	Management and complete resection of peritoneal and bone metastases from mucinous rectal carcinoma. Tumori, 2020, 107, 030089162097769.	1.1	1
17	Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases. European Journal of Surgical Oncology, 2020, 46, 737-739.	1.0	7
18	Hemodynamic and respiratory implications of high intra-abdominal pressure during HIPEC. European Journal of Surgical Oncology, 2020, 46, 1896-1901.	1.0	7

#	Article	IF	Citations
19	Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination. , 2020, , 117-129.		2
20	Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multiâ€institutional experience. Journal of Surgical Oncology, 2019, 119, 336-346.	1.7	31
21	Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience. European Journal of Surgical Oncology, 2019, 45, 2103-2108.	1.0	10
22	Peritoneal Mesothelioma: Diagnosis and Management. , 2019, , 301-322.		0
23	RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score. Annals of Surgical Oncology, 2019, 26, 2595-2604.	1.5	25
24	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. Clinical Colorectal Cancer, 2019, 18, e179-e190.	2.3	12
25	Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma. International Journal of Molecular Sciences, 2019, 20, 5817.	4.1	11
26	Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. European Journal of Surgical Oncology, 2019, 45, 371-375.	1.0	13
27	Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. Annals of Surgical Oncology, 2018, 25, 878-884.	1.5	55
28	Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Annals of Surgical Oncology, 2018, 25, 667-673.	1.5	25
29	Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. European Journal of Surgical Oncology, 2018, 44, 1100-1104.	1.0	24
30	Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. European Journal of Surgical Oncology, 2018, 44, 792-798.	1.0	21
31	Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2018, 25, 404-413.	1.5	61
32	ASO Author Reflections: Pathologic Classification of Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2018, 25, 844-845.	1.5	1
33	Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter internationalÂstudy. European Journal of Surgical Oncology, 2018, 44, 1786-1792.	1.0	22
34	Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers. Surgical Oncology Clinics of North America, 2018, 27, 507-517.	1.5	27
35	Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC. Annals of Surgical Oncology, 2018, 25, 3264-3270.	1.5	20
36	Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?. Diseases of the Colon and Rectum, 2018, 61, 1026-1034.	1.3	25

#	Article	IF	Citations
37	Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups. European Journal of Surgical Oncology, 2018, 44, 1378-1383.	1.0	20
38	Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. European Journal of Surgical Oncology, 2017, 43, 2170-2177.	1.0	17
39	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. Annals of Surgical Oncology, 2017, 24, 167-175.	1.5	41
40	Cytoreductive Surgery and HIPEC in the First-Line and Interval Time Points of Advanced Epithelial Ovarian Cancer. Indian Journal of Gynecologic Oncology, 2017, 15, 11-20.	0.3	6
41	Colorectal Cancer Peritoneal Metastases. Annals of Surgery, 2016, 263, e5.	4.2	3
42	Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. Annals of Surgical Oncology, 2016, 23, 4222-4230.	1.5	30
43	The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2016, 23, 1468-1473.	1.5	59
44	Toward the molecular dissection of peritoneal pseudomyxoma. Annals of Oncology, 2016, 27, 2097-2103.	1.2	59
45	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. Journal of Translational Medicine, 2016, 14, 125.	4.4	36
46	Commment on the review entitled â€œA critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancerâ€•by Chiva LM and Gonzalez-Martin A.. Gynecologic Oncology Reports, 2016, 15, 7-8.	0.6	3
47	Progress in treatments for colorectal cancer peritoneal metastases during the years 2010â€“2015. A systematic review. Critical Reviews in Oncology/Hematology, 2016, 100, 209-222.	4.4	92
48	The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Surgical Oncology, 2015, 41, 1097-1105.	1.0	22
49	Epidural analgesia for cytoreductive surgery with peritonectomy and heated intraperitoneal chemotherapy. International Journal of Surgery, 2015, 16, 99-106.	2.7	22
50	The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma. Journal of Surgical Oncology, 2015, 111, 570-579.	1.7	11
51	In Reply. Oncologist, 2015, 20, e5-e5.	3.7	1
52	Peritoneal Mesothelioma. Updates in Surgery Series, 2015, , 243-254.	0.1	0
53	Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIÎ±, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray. Annals of Surgical Oncology, 2015, 22, 4344-4351.	1.5	21
54	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. Oncologist, 2014, 19, 845-850.	3.7	48

#	Article	IF	Citations
55	Prevention and early treatment of peritoneal metastases from colorectal cancer: Secondâ€look laparotomy or prophylactic HIPEC?. Journal of Surgical Oncology, 2014, 109, 225-226.	1.7	8
56	Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Affect Long-term Outcome of Patients With Peritoneal Metastases From Colorectal Cancer. Diseases of the Colon and Rectum, 2014, 57, 858-868.	1.3	106
57	Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. British Journal of Surgery, 2014, 101, 1758-1765.	0.3	68
58	The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Journal of Surgical Oncology, 2014, 110, 779-785.	1.7	134
59	The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Annals of Surgical Oncology, 2014, 21, 4195-4201.	1.5	141
60	Carboplatin plus paclitaxel scheduling for advanced ovarian cancer. Lancet Oncology, The, 2014, 15, e249.	10.7	3
61	The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2013, 20, 1093-1100.	1.5	78
62	Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Cancer, 2013, 49, 3140-3148.	2.8	110
63	Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. European Journal of Surgical Oncology, 2013, 39, 742-747.	1.0	27
64	Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: Analysis of two centres. Journal of Surgical Oncology, 2013, 107, 312-319.	1.7	69
65	Circulating tumor markers: Predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei. Journal of Surgical Oncology, 2013, 108, 1-8.	1.7	30
66	Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer. Obstetrical and Gynecological Survey, 2013, 68, 359-360.	0.4	0
67	Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. Tumori, 2013, 99, 589-595.	1.1	11
68	Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. Tumori, 2013, 99, 589-95.	1.1	9
69	Importance of gender in diffuse malignant peritoneal mesothelioma. Annals of Oncology, 2012, 23, 1494-1498.	1.2	47
70	Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Clinical Oncology, 2012, 30, 2449-2456.	1.6	873
71	Multidimensional Analysis of the Learning Curve for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Surface Malignancies. Annals of Surgery, 2012, 255, 348-356.	4.2	116
72	Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgery, 2012, 256, 334-341.	4.2	70

#	Article	IF	Citations
73	The Importance of the Learning Curve and Surveillance of Surgical Performance in Peritoneal Surface Malignancy Programs. Surgical Oncology Clinics of North America, 2012, 21, 559-576.	1.5	30
74	Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multiâ€institutional study. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 800-809.	2.3	68
75	Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study. Annals of Surgical Oncology, 2012, 19, 1416-1424.	1.5	85
76	Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. European Journal of Surgical Oncology, 2011, 37, 4-9.	1.0	74
77	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial. Gynecologic Oncology, 2011, 122, 215-220.	1.4	131
78	Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research. Journal of Surgical Oncology, 2011, 103, 822-831.	1.7	62
79	Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma. Annals of Surgical Oncology, 2010, 17, 45-53.	1.5	72
80	In Reply: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must Be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma. Annals of Surgical Oncology, 2010, 17, 1713-1714.	1.5	2
81	Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?. Annals of Surgical Oncology, 2010, 17, 3220-3228.	1.5	83
82	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Peritoneal Mesothelioma and HIV Infection. Tumori, 2010, 96, 340-344.	1.1	3
83	Pathophysiology and biology of peritoneal carcinomatosis. World Journal of Gastrointestinal Oncology, 2010, 2, 12.	2.0	74
84	Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. European Journal of Cancer, 2010, 46, 2837-2848.	2.8	30
85	Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Surgical Oncology, 2010, 36, 463-469.	1.0	41
86	Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). European Journal of Surgical Oncology, 2010, 36, 1047-1053.	1.0	37
87	Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World Journal of Gastrointestinal Oncology, 2010, 2, 36.	2.0	45
88	Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World Journal of Gastrointestinal Oncology, 2010, 2, 76.	2.0	22
89	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. Journal of Clinical Oncology, 2009, 27, 6237-6242.	1.6	598
90	Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. Journal of Surgical Oncology, 2009, 100, 321-328.	1.7	91

#	Article	IF	Citations
91	Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2009, 16, 463-472.	1.5	46
92	Circulating CA125 and diffuse malignant peritoneal mesothelioma. European Journal of Surgical Oncology, 2009, 35, 1198-1199.	1.0	14
93	Pseudomyxoma Peritonei. Annals of Surgery, 2009, 249, 243-249.	4.2	90
94	Surgical Treatment of Peritoneal Carcinomatosis. , 2009, , 229-236.		0
95	Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. Journal of Surgical Oncology, 2008, 98, 247-252.	1.7	98
96	Locoregional treatment of peritoneal carcinomatosis from gastric cancer. Journal of Surgical Oncology, 2008, 98, 273-276.	1.7	77
97	Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. Journal of Surgical Oncology, 2008, 98, 263-267.	1.7	180
98	Consensus statement on the locoâ€regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). Journal of Surgical Oncology, 2008, 98, 277-282.	1.7	193
99	Consensus statement on peritoneal mesothelioma. Journal of Surgical Oncology, 2008, 98, 268-272.	1.7	92
100	The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4â€“6, 2006): methodology of diseaseâ€specific consensus. Journal of Surgical Oncology, 2008, 98, 258-262.	1.7	29
101	Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. Journal of Surgical Oncology, 2008, 98, 253-257.	1.7	84
102	Technical aspects of cytoreductive surgery. Journal of Surgical Oncology, 2008, 98, 232-236.	1.7	20
103	The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy. Journal of Surgical Oncology, 2008, 98, 217-219.	1.7	17
104	The eligibility for localâ€regional treatment of peritoneal surface malignancy. Journal of Surgical Oncology, 2008, 98, 220-223.	1.7	37
105	Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion. Journal of Surgical Oncology, 2008, 98, 242-246.	1.7	122
106	The consensus statement on the locoregional treatment of abdominal sarcomatosis. Journal of Surgical Oncology, 2008, 98, 291-294.	1.7	36
107	The intraoperative staging systems in the management of peritoneal surface malignancy. Journal of Surgical Oncology, 2008, 98, 228-231.	1.7	104
108	Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: Expert consensus statement. Journal of Surgical Oncology, 2008, 98, 224-227.	1.7	78

#	Article	IF	Citations
109	Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. Journal of Surgical Oncology, 2008, 98, 237-241.	1.7	56
110	Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. Journal of Surgical Oncology, 2008, 98, 283-290.	1.7	56
111	Pseudomyxoma Peritonei: Clinical Pathological and Biological Prognostic Factors in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2008, 15, 526-534.	1.5	167
112	Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma. Clinical Cancer Research, 2008, 14, 4134-4140.	7.0	61
113	Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). In Vivo, 2008, 22, 153-7.	1.3	17
114	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement. Annals of Surgical Oncology, 2007, 14, 128-133.	1.5	390
115	Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. Annals of Surgical Oncology, 2007, 14, 500-508.	1.5	72
116	Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2007, 14, 2300-2308.	1.5	87
117	Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity. Annals of Surgical Oncology, 2007, 14, 2550-2558.	1.5	69
118	Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2007, 14, 2790-2797.	1.5	45
119	Incidence of Postoperative Pancreatic Fistula and Hyperamylasemia after Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2007, 14, 3443-3452.	1.5	23
120	Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. Annals of Surgical Oncology, 2007, 14, 3542-3551.	1.5	86
121	Morbidity and Quality of Life following Cytoreduction and HIPEC. , 2007, 134, 403-418.		10
122	Advances in Clinical Research and Management of Diffuse Peritoneal Mesothelioma. , 2007, 169, 137-155.		3
123	Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma. Analytical Cellular Pathology, 2007, 29, 453-466.	1.4	35
124	Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. European Journal of Surgical Oncology, 2006, 32, 671-675.	1.0	105
125	CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology, 2006, 49, 381-387.	2.9	46
126	Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. Annals of Surgical Oncology, 2006, 13, 229-237.	1.5	144

#	Article	IF	Citations
127	Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion. Cancer, 2006, 106, 1144-1153.	4.1	234
128	Bowel Complications in 203 Cases of Peritoneal Surface Malignancies Treated With Peritonectomy and Closed-Technique Intraperitoneal Hyperthermic Perfusion. Annals of Surgical Oncology, 2005, 12, 910-918.	1.5	69
129	Diffuse malignant mesothelioma of the peritoneum. Cancer, 2005, 104, 2181-2188.	4.1	82
130	Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2004, 11, 393-398.	1.5	157
131	Uterine Sarcoma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion: a Feasiblity Study. Journal of Chemotherapy, 2004, 16, 19-22.	1.5	13
132	Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. Journal of Surgical Oncology, 2003, 83, 147-153.	1.7	77
133	Chordoma: Natural History and Results in 28 Patients Treated at a Single Institution. Annals of Surgical Oncology, 2003, 10, 291-296.	1.5	204
134	Preoperative chemoradiation in patients with resectable rectal cancer: Results on tumor response. Annals of Surgical Oncology, 2002, 9, 444-449.	1.5	28
135	Post-absorptive and insulin-mediated muscle protein metabolism in liver-transplanted patients. Acta Diabetologica, 2002, 39, 203-208.	2.5	6
136	Preoperative Chemoradiation in Patients With Resectable Rectal Cancer: Results on Tumor Response. Annals of Surgical Oncology, 2002, 9, 444-449.	1.5	1
137	Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation. Hepatology, 2000, 31, 694-703.	7.3	114
138	Surgical Strategies in Colorectal Cancer Metastatic to the Liver. Tumori, 2000, 86, 1-7.	1.1	3
139	Preoperative radiation therapy for patients with T2-T3 carcinoma of the middle-to-lower rectum. Cancer, 1999, 86, 398-404.	4.1	43
140	Effect of liver transplantation in cirrhotic diabetic patients. Transplantation Proceedings, 1998, 30, 1868.	0.6	2
141	Renal-splenic shunt for infrahepatic caval occlusion after piggy-back liver transplantation. Transplant International, 1997, 10, 392-394.	1.6	3
142	Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplantation Proceedings, 1997, 29, 519-521.	0.6	92
143	Impact of Distal Clearance Margin on Oncologic Outcome after Restorative Resection of the Rectum. Tumori, 1997, 83, 907-911.	1.1	9
144	Renal-splenic shunt for intrahepatic caval occlusion after piggy-back liver transplantation. Transplant International, 1997, 10, 392-394.	1.6	3

#	Article	IF	Citations
145	Surgical treatment of locally recurrent rectal carcinoma. Diseases of the Colon and Rectum, 1997, 40, 1421-1424.	1.3	63
146	Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma. Journal of Viral Hepatitis, 1997, 4, 235-242.	2.0	6
147	Metabolic effects of liver transplantation in cirrhotic patients.. Journal of Clinical Investigation, 1997, 99, 692-700.	8.2	45
148	Regulation of glucose homeostasis in humans with denervated livers.. Journal of Clinical Investigation, 1997, 100, 931-941.	8.2	95
149	Preoperative radiotherapy for resectable cancer of the middle-distal rectum: its effect on the primary lesion as determined by endorectal ultrasound using flexible echo colonoscope. International Journal of Colorectal Disease, 1996, 11, 283-286.	2.2	27
150	Avidin-biotin system in Radioimmunoguided surgery for colorectal cancer. Diseases of the Colon and Rectum, 1994, 37, 335-343.	1.3	14
151	Surgery for colorectal cancer guided by radiodetecting probe. Clinical evaluation using monoclonal antibody B72.3. The European Journal of Surgery, 1991, 157, 485-8.	0.9	4